If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Acquisition & Research Agreement

13 Sep 2010 07:00

RNS Number : 5363S
Immunodiagnostic Systems Hldgs PLC
13 September 2010
 



Immunodiagnostic Systems Holdings plc

 

Acquisition and Research Agreement

 

Immunodiagnostic Systems Holdings plc ("IDS"), a leading producer of diagnostic testing kits for the clinical and research markets, announces that it has acquired 100% of the share capital of MGP Diagnostics AS of Mjøndalen, Norway (MGPD) for an undisclosed cash consideration.

 

MGPD is a non-trading company owning a portfolio of patents relating to the determination of a unique biomarker called Matrix GLA protein (mGLA). There is growing evidence that mGLA is a controlling factor in the inappropriate calcification of soft tissues such as the carotid arteries and heart valves, with an increasing number of publications appearing in the scientific literature in recent years.

 

Vascular calcification is known to play a significant role in the development of cardiovascular disease (CVD). It is particularly common in patients suffering from chronic kidney disease (CKD) and those on kidney dialysis, who commonly develop bone disease as a result of their failing kidneys. More than 80% of dialysis patients develop some degree of coronary artery calcification.

 

IDS also announces that it has entered into a Research Agreement with VitaK BV of Maastricht in the Netherlands. VitaK is the leading research establishment in mGLA biology in the world, having filed the original patents now acquired by IDS from MGPD. IDS and VitaK will work closely to accelerate the proof of concept studies needed to establish the clinical utility of mGLA.

 

Dr Roger Duggan, CEO of IDS, commented: "This acquisition provides IDS with an IP-protected entry into an adjacent, highly complementary area of potential clinical importance. Calcification of bones and teeth is highly desirable, but in soft tissues such as arteries and heart valves is potentially lethal. The future availability of a serum biomarker for early diagnosis and the monitoring of therapy will provide a valuable tool to cardiovascular and renal physicians throughout the world."

 

For further information:

 

Immunodiagnostic Systems Holdings PLC

Tel: 0191 519 0660

Roger Duggan, CEO

Ian Cookson, COO

Paul Hailes, Finance Director

Walbrook PR Ltd

Tel: 020 7933 8787

Paul McManus

Mob: 07980 541 893

paul.mcmanus@walbrookpr.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAKKBDBDBKDNCD
Date   Source Headline
14th Dec 20127:00 amRNSDirectorate Change
12th Dec 20124:00 pmRNSHolding(s) in Company
12th Dec 20127:00 amRNSHolding(s) in Company
10th Dec 20126:08 pmRNSHolding(s) in Company
30th Nov 20126:15 pmRNSDirector/PDMR Shareholding
26th Nov 20127:00 amRNSHalf Yearly Report
24th Oct 201210:59 amRNSNotice of Results
19th Oct 20127:00 amRNSDirectorate Change Update
17th Oct 201211:41 amRNSSettlement on Escalon debt
1st Oct 201210:31 amRNSHolding(s) in Company
17th Sep 201212:54 pmRNSRedirectorate
14th Sep 20126:09 pmRNSAGM Result
14th Sep 20127:00 amRNSAGM Statement
15th Aug 20127:00 amRNSBoard Change
3rd Aug 20122:33 pmRNSDirector/PDMR Shareholding
30th Jul 201210:18 amRNSHolding(s) in Company
27th Jul 20129:29 amRNSHolding(s) in Company
27th Jul 20129:24 amRNSHolding(s) in Company
26th Jul 201210:30 amRNSAnnual Report and Accounts & Notice of AGM
2nd Jul 20127:00 amRNSDirectorate Change
25th Jun 20127:00 amRNSFinal Results
14th Jun 20127:00 amRNSProduct Launch
23rd Apr 201211:02 amRNSIDS Receives Prestigious Queens Award
12th Apr 20127:00 amRNSTrading Statement
4th Apr 20129:56 amRNSHolding(s) in Company
4th Apr 20127:00 amRNS1,25-Dihydroxy Vitamin D Assay Launch
14th Feb 20127:00 amRNSFDA clearance for a new specialist assay
9th Feb 20127:00 amRNSChange of Adviser
1st Feb 20123:16 pmRNSChange of Adviser
30th Jan 20128:27 amRNSDirector/PDMR Shareholding - Replacement
30th Jan 20127:00 amRNSDirector/PDMR Shareholding
30th Jan 20127:00 amRNSDirector/PDMR Shareholding
27th Jan 20127:00 amRNSDirector/PDMR Shareholding
24th Jan 20123:18 pmRNSHolding(s) in Company
24th Jan 20122:38 pmRNSHolding(s) in Company
23rd Jan 20127:01 amRNSTrading update
12th Jan 201212:13 pmRNSHolding(s) in Company
15th Dec 201111:02 amRNSHolding(s) in Company
30th Nov 20115:23 pmRNSTotal Voting Rights
28th Nov 20117:00 amRNSInterim Results
14th Nov 20112:03 pmRNSIssue of Equity
6th Oct 20117:00 amRNSTrading Update
4th Oct 20112:45 pmRNSHolding(s) in Company
8th Sep 20115:22 pmRNSResult of AGM
8th Sep 20117:00 amRNSAGM Statement
31st Aug 20114:35 pmRNSPrice Monitoring Extension
30th Aug 20117:00 amRNSDirectorate Change
25th Jul 20117:00 amRNSDirectorate Change
29th Jun 20114:50 pmRNSExercise of Options & Total Voting Rights
27th Jun 20117:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.